Results of a phase 3 PURPOSE 1 HIV prevention study done among adolescent girls and young women in South Africa and Uganda show that there were no...
Vous n'êtes pas connecté
Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.
Results of a phase 3 PURPOSE 1 HIV prevention study done among adolescent girls and young women in South Africa and Uganda show that there were no...
An injection containing the antiretroviral drug lenacapavir is highly effective at preventing HIV infection for six months per shot. This is according...
A promising new HIV prevention drug called lenacapavir has shown 100 percent efficacy in a clinical trial among adolescent girls and young women in...
None of the over 2,000 young women and girls injected twice a year with a new drug, lenacapavir, contracted HIV in one of the most important advances...
WHO estimates that there are 39 million HIV patients living in the world with a death rate of around 630,000 per year. A figure that seems high but 20...
Injectable HIV Prevention Drug Shows Promising Results By Thuku Kariuki and Daniel Furnad An injectable medication to prevent the transmission of HIV,...
MONDAY, June 24, 2024 -- Just two injections a year of a new HIV drug protected young women in Africa from infection with the sexually transmitted...
Gilead Sciences (GILD) closed the most recent trading day at $69.61, moving -1.58% from the previous trading session.
Drug-resistant disease-causing microbes can infect any one of us. Bhakti Chavan, a promising biotechnologist, who never had TB before, got infected...
Extension of First Home Scheme follows latest of its scheduled twice-yearly reviews of the price ceilings